Acoustic Nonlinearity in Metal — Matrix Composites

The elastic behavior of a solid consists of linear and nonlinear contributions. The linear part is represented by the well known Hooke’s law which is given in tensorial notation as (1) σij=Cijklεkl where σij and εkl are the stress and strain tensors, respectively, and Cijkl is the tensor of the second order elastic constants (SOEC). This relationship is sufficient for many engineering calculations since deviations from a purely linear elastic behavior are small. Hooke’s law, however, is not sufficient for an advanced characterization of the elastic behavior of materials. This is due to the fact that many of the physical and mechanical properties of materials are of nonlinear nature. The nonlinear elastic behavior can be investigated using ultrasonic techniques because of their high sensitivity for small nonlinear effects. Among the nonlinear effects are the stress and the temperature dependences of ultrasonic velocities in the solid. These effects have gained considerable interest in the last decade, particularly for the nondestructive evaluation of applied and residual stresses [1], and also for the microstructural characterization of materials [2]. Another physical manifestation of the nonlinear elastic behavior of solids is the acoustic nonlinearity parameter. This parameter can be determined from measurements of the amplitudes of fundamental and second harmonic when an originally sinusoidal wave gets distorted while propagating through the solid. The nonlinearity parameter can also be calculated from a combination of second and third order elastic constants. In previous studies [3], the nonlinearity parameter was found to be sensitive to microstructural changes in aluminum alloys and in particular to the content of precipitates of the second phase.</p

Effect of quenching strategy and Nb-Mo sdditions on phase transformations and quenchability of high-strength boron steels

The application of direct quenching after hot rolling of plates is being employed in the production of ultra-high-strength hot rolled plates. When heavy gauge plates are produced, the complexity involve in achieving high cooling rates in the plate core is increased and the formation of undesirable soft phases within martensite is common. In the current paper, both direct quenching and conventional quenching (DQ and CQ) processing routes were reproduced by dilatometry tests and continuous cooling transformation (CCT) diagrams were built for four different high-strength boron steels. The results indicate that the addition of Mo and Nb-Mo suppresses the ferritic region and considerably shifts the CCT diagram to lower transformation temperatures. The combination of DQ strategy and the Mo-alloying concept provides the best option to ensure hardenability and the formation of a fully martensitic microstructure, and to avoid the presence of soft phases in the center of thick plates

Molybdenum alloying in high-performance flat-rolled steel grades

Considerable progress in developing flat-rolled steel grades has been made by the Chinese steel industry over the recent two decades. The increasing demand for high-performance products to be used in infrastructural projects as well as in production of consumer and capital goods has been driving this development until today. The installation of state-of-the-art steel making and rolling facilities has provided the possibility of processing the most advanced steel grades. The production of high-performance steel grades relies on specific alloying elements of which molybdenum is one of the most powerful. China is nearly self-sufficient in molybdenum supplies. This paper highlights the potential and advantages of molybdenum alloying over the entire range of flat-rolled steel products. Specific aspects of steel property improvement with respect to particular applications are indicated

A 160-Gb/s OTDM demultiplexer based on parametric wavelength exchange

Parametric wavelength exchange (PWE) has been demonstrated as a versatile device in providing different functionalities. In this paper, we will concentrate, numerically and experimentally, on one of these functionalities, namely, all-optical time demultiplexing of 160-Gb/s return-to-zero (RZ) signals based on a pulsed-pump PWE in a 400 m highly nonlinear dispersion-shifted fiber. Experimental results show power penalties &lt; 2.7 dB at bit-error rate of 10-9 for all demultiplexed 10-Gb/s RZ signals. We also derive theoretical expressions for the conversion/residual efficiencies and investigate the impact of pump pulse width and phase mismatch on these efficiencies. Furthermore, the impacts of pulsed-pump wavelength and power level on the characteristics of the switching window are investigated numerically. As a result, the demultiplexer can be easily upgraded to an add-drop multiplexer because of the complete exchange nature of PWE, which is justified by the surviving channels' waveform performance. © 2009 IEEE.published_or_final_versio

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

Genome-wide association studies (GWAS) in European populations have identified genetic risk variants associated with multiple myeloma (MM)

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals